

Kindred Biosciences, Inc.

Fact Sheet

K I N

L I S T E D

N Y S E

Kindred Biosciences, Inc. <> KIN

Kindred Biosciences to Announce Second Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, August 9, 2018

Kindred Biosciences will release its second quarter 2018 financial results on August 9, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.

Interested parties may access the call by dialing toll-free
(855) 433-0927 from the US
(484) 756-4262 internationally
Using conference ID 4789665.

RECENT PRESS RELEASES (Headlines and Excerpts)

Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

July 9, 2018 -- Kindred Biosciences, Inc. announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States.

Mirataz is the first and only transdermal medication for the management of weight loss in cats approved by the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine. Unintended weight loss in cats is a serious and potentially fatal condition that represents the leading cause of visits to the veterinarian for cats. Mirataz is a serotonin (5HT_{2A}, 5HT_{2C}, and 5HT₃) and histamine (H₁) receptor antagonist, which has demonstrated body weight gain in cats experiencing weight loss. The product is classified as a weight gain drug and can be used in cats experiencing unintended weight loss caused by varying underlying conditions. Formulated with KindredBio's proprietary Accusorb™ technology, Mirataz is applied topically to the cat's inner ear (pinna) once a day, providing an attractive application route instead of oral dosing.

"With approximately nine million cats experiencing unintended weight loss due to underlying conditions each year, we are very pleased to offer this first-in-class therapy to veterinarians," stated Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio. "As our first approved product, Mirataz confirms our strategy of quickly and cost-efficiently developing animal health therapeutics. Furthermore, the speed with which our team brought this product to market following FDA-approval illustrates the caliber of talent within our commercial, operations, and supply-chain teams."

Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

June 25, 2018 -- Kindred Biosciences, Inc. announced the underwriters have exercised in full their option to purchase an additional 694,736 shares of KindredBio's common stock at \$9.50 per share, less underwriting discounts and commissions. KindredBio also announced that it has closed its public offering of 5,326,314 shares of common stock at a public offering price of \$9.50 per share, which included the sale of the shares pursuant to the option to purchase additional shares, for a total offering amount of approximately \$50.6 million before deducting underwriting discounts and commissions and offering expenses payable by KindredBio.

Cantor Fitzgerald & Co. acted as sole book-running manager for the offering. B. Riley FBR acted as co-manager. A.G.P. / Alliance Global Partners, H.C. Wainwright & Co., Ladenburg Thalmann, and Lake Street Capital Markets LLC provided financial advisory services.

KindredBio intends to use the net proceeds from the offering for the expansion of its commercial infrastructure in anticipation of future product approvals and launches, for expansion of its manufacturing capacity, the development of its therapeutic candidates, and for other general corporate and working capital purposes.

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information regarding Kindred Biosciences Inc. is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

KINDRED BIOSCIENCES

QUICK REFERENCE

Company: Kindred Biosciences, Inc.

Ticker Symbol: NYSE: KIN

Shares Outstanding: 33,601,000

Web: www.KINDREDBIO.com

BUSINESS SUMMARY

KindredBio develops breakthrough medicines for cats, dogs, and horses.

Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz[®] (mirtazapine transdermal ointment) for the management of weight loss in cats.

PRODUCTS

Mirataz[™] (mirtazapine transdermal ointment) is the FIRST AND ONLY FDA-approved transdermal medication for the management of weight loss in cats.

- In clinical studies, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2 mg per day¹
- Mirataz gives your clients a practical way to manage their cat's weight loss without administration of oral medication and does not rely on the cat to eat to be medicated
- Due to proprietary Accusorb[™] technology, Mirataz achieves measurable plasma concentrations of mirtazapine in cats²
- Mirataz was well tolerated both locally and systemically in clinical studies

PIPELINE

- Zimeta[™] Injection ~ Control of fever in horses
- Zimeta[™] Oral ~ Control of fever in horses
- epoCat[™] ~ Control of non-regenerative anemia in cats
- IL31 Antibody ~ Atopic dermatitis in dogs
- IL17 Antibody ~ Atopic dermatitis in dogs
- IL4/13 SINK ~ Atopic dermatitis in dogs

CONTACT INFORMATION

Headquarters
1555 Bayshore Highway
Burlingame, CA 94010

Investor Relations
Andrew Barwicki
1-516-662-9461 /andrew@barwicki.com

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Kindred Biosciences, Inc.

Trading Symbol: *KIN*

www.KINDREDBIO.com

Banwiski Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: